Hatch BioFund Announces New Partnership with Brandywine Realty Trust <<more here>>

Living Science

The Baruch S. Blumberg Institute is the nation’s leading translational research organization dedicated to finding a cure for hepatitis B and liver cancer in our lifetime.

Our Life-Saving Liver Disease Research Depends on People Like You

The Baruch S. Blumberg Institute is the nation’s leading nonprofit translational research organization dedicated to finding a cure for HBV and liver cancer in our lifetime. We find new solutions through research programs, which include drug research, biomarker discovery and other forms of biotechnology. With our goal being cures for diseases such as chronic hepatitis, liver disease and liver cancer, we do all of our research in environments that are conducive to interaction, collaboration and focus.

Upcoming Seminars

  • Distinguished Speaker Seminar Series

    We host a distinguished professional Seminar Series to promote scientific exchange at a national and international level. Renowned leaders in the field are invited to speak on a regular schedule, which is free and open to the interested public.

Research Highlights

Blumberg Institute awarded federal research contract worth up to $32 million to develop treatment for yellow fever

The Baruch S. Blumberg Institute has been awarded a one-year contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to develop a potential treatment for yellow fever, an often-deadly disease that has no cure. Please read more here

Certificate Program in Pharmaceutical Research & Development

The Baruch S. Blumberg Institute has been making breakthroughs in drug discovery and development for nearly 20 years. Several of our scientists have successfully translated their scientific discoveries into FDA-approved drugs, which is a rare and remarkable feat. The institute is unique as it offers a conducive environment with a combination of academics and biotechnology industries. Please read more here

The Blumberg Institute receives angel investment state funding thanks to Sen. Pat Browne

The Baruch S. Blumberg Institute’s Academic Entrepreneur Initiative will receive a $2 million grant from the state’s Angel Investment Venture Capital Program, according to Senate Majority Appropriations Committee Chairman Pat Browne (R-Lehigh), who developed the program in coordination with the Governor’s office, the Office of the Budget and Senator Steve Santarsiero (D-Bucks).  Please read more here.

Blumberg spinout wins pitch competition at Biotech Week Boston 

At Biotech Week Boston, one of the industry’s largest events with over 4,000 participants spanning the drug development value chain, MERLIN Biotech CEO Randall N. Hyer, MD, PhD, MPH, won the Startup Springboard competition against 11 other highly selected startup companies. Please read more here.

Blumberg Institute Laboratory dedicated to liver cancer research in memory of Johnson & Johnson Consumer Inc. manager, a Doylestown-area resident

Steven W. Miller, who was widely respected and loved by his colleagues at Johnson & Johnson Consumer Inc., died in 2020 from liver cancer caused by metabolic associated fatty liver disease (MAFLD), a chronic illness for which symptoms don’t emerge until the latter stages. Please read more here.

Randall N. Hyer, MD, PhD, MPH, former Moderna executive, named president of the Baruch S. Blumberg Institute

The Baruch S. Blumberg Institute’s Board of Directors has appointed Randall N. Hyer, MD, PhD, MPH, former senior vice president for global medical affairs at Moderna Inc., to become the Institute’s next president, effective July 1. Please read more here.

Blumberg Institute Faculty News 

Following is noteworthy news about people working at the Baruch S. Blumberg Institute, which is the research arm of the Hepatitis B Foundation. Please read more here

Baruch S. Blumberg Institute launches MERLIN Biotech, a spinout company leveraging mRNA technology for therapeutics and vaccines

The Baruch S. Blumberg Institute has announced the launch of MERLIN Biotech, a new platform biotechnology spinout company leveraging proven mRNA technology to develop novel therapeutics and vaccines against targets that address important unmet medical needs, including chronic hepatitis B infections, adult and pediatric cancers, and Lyme disease. Please read more here

Thank you very much to the great folks at Fred Beans for supporting our education programs!

six students cropped BSBI



Preventing the Spread of HBV

The hepatitis virus has been affecting various parts of the world, with the worst of it being in Africa and areas of Southeast Asia, as well as China, Japan and India. The United States has felt the effects of liver disease as well, especially with the rise of the opioid crisis. Sharing needles is one of the most common ways that liver disease is spread, and with opioid abuse on the rise in states from California to Pennsylvania, hepatitis B and liver cancer cases are becoming more and more frequent.

The goal of the Baruch S. Blumberg Institute is to prevent hepatitis B from spreading as a result of the opioid crisis and other common causes. We also aim to find ways to help those who are living with liver disease anywhere from California to Japan to India with better methods of treatment. Our non-profit research center extends our solutions to anyone battling Hep B through living science.


The Hepatitis B Foundation

The Baruch S. Blumberg Institute is proudly associated with the Hep B Foundation, a national non-profit organization that has been committed to researching and finding a cure for viral hepatitis for over two decades. Through beginnings as a local organization New Hope, Pa., the foundation has grown into a movement with a global reach. From the United States to China and countries in Southeast Asia, the Hep B Foundation has made its presence known and has put together a variety of international programs focused on raising awareness of liver disease.

You can learn more about the Hep B Foundation here.


Donate to cure Hep B.

The Baruch S. Blumberg Institute is making breakthroughs every day to combat chronic hepatitis, but we can’t do it alone. As a non-profit organization, we rely almost exclusively on funding and donations to power our hepatitis virus research, and those donations come from people like you. When you donate to cure Hep B, you are allowing our researchers to have more access to the resources and technologies that make finding a cure possible.

We humbly encourage you to consider making a donation to the Baruch S. Blumberg Institute. We are a non-profit organization, which means every cent of your donation is going toward medical research for discovering new ways to combat liver disease. With your help, we can help put an end to liver cancer and hepatitis B once and for all.

Donate Today

Areas of Focus

  • focus5

    Drug Discovery & Medicinal Chemistry

    Discovering new medicines for hepatitis B, liver cancer, and other forms of viral hepatitis through integrated chemical and biological approaches. Learn more.

  • focus2

    Biomarker Discovery

    Discovering biomarkers for liver diseases and early, non-invasive diagnosis of liver cancers. Learn more.

  • focus3

    Viral Pathogenesis

    Exploring the mechanism of hepatitis B virus infection and identifying molecular targets for curative therapeutics.

  • focus4

    PCRMRC Research Center

    Translating discoveries in cancer, with a focus on the role of cell and tissue engineering,  and metabolism governing these processes. Learn more.

  • public health

    Public Health

    Decreasing the burden of disease and death from hepatitis B and liver cancer by increasing awareness, testing, and linkage, to cure, prevent, and control these life-threatening liver diseases.Learn more.

  • focus6

    Academic Programs

    Exceptional educational opportunities that combine rigorous academic learning, practical experience, and the use of advanced technologies, for students at every level. Learn more.